Will China’s plan to kickstart Shanghai’s supply chains actually work?
One of the major problems we at The Loadstar have faced in reporting on Shanghai’s ...
© Robert Byron
By Alex Lennane
As Moderna announces near-95% efficacy in its new Covid-19 vaccine trial, the focus on distribution has become even more intense.
The latest vaccine from the US company could be ready to ship next year, with Moderna saying it hopes to make 500 million to 1 billion doses in 2021.
It will be easier to distribute than the Pfizer version, as Moderna claims it is more stable, can be kept at between 2C and 8C for up to 30 days and can be stored for six months at -20C. Pfizer’s vaccine requires ultracold freezing at between -70C and -80C.
The Logistics & Supply Chain Management Society and IDC have written a research paper advocating the use of a Vaccine Distribution Ecosystem in a public-private partnership that “orchestrates the private and public networks to ensure that populations are effectively inoculated”.
Comment on this article